Abstract: A method of predicting the development of chronic lung allograft dysfunction (CLAD) in lung transplant patients using N-myc-interactor (NMI) as a biomarker and associated treatment thereof is presented. Also presented is a method of reducing the risk of CLAD by administering a therapeutic agent capable of increasing NMI in the patient. NMI is a critical regulator of epithelial-to-mesenchymal transition (EMT) and an important precursor to development of CLAD. NMI expression is reduced in CLAD patients and can be used as an early diagnostic biomarker to predict the development of CLAD. NMI can also be used as a drug target for a therapeutic to increase expression of NMI and treat chronic lung disease such as CLAD. Therapeutics comprising NMI protein or NMI gene can be used as potential treatments for chronic lung diseases such as CLAD.

Abstract: A formulation is especially suited as one or more of an insecticide, anti-viral, anti-bacterial, anti-fungicide as well as one that acts as a fertilizer and/or an enhancement to a fertilizer when the formulation is coated thereon. The formulation can be used to treat plants for pest control and/or fertilization or other areas in that require a viral, fungal, and/or bacterial treatment.

Abstract: The present invention is directed to nanosuspensions of salsalate and methods of making and using such compositions.

Abstract: The present invention concerns carrier particles suitable for use in dry powder formulations for inhalation. The invention also relates to processes for their preparation by spray-congealing.

Abstract: A method for producing a biocide from a hypochlorite oxidant and an ammonium salt is provided. The method focuses on preventing and/or reducing the presence of excess ammonium. The molar ratio of ammonium to hypochlorite is less than 1:1. In a preferred embodiment, the method includes monitoring the conductivity of the biocide to optimize the ratio between the hypochlorite oxidant and the ammonium salt. The optimum ratio is that at which the conductivity has a local maximum.

Abstract: Methods of increasing soil water content are described. The methods may include applying a soil enhancement agent to the soil, where the soil enhancement agent includes one or both of (i) lactobionic acid and (ii) at least one salt of lactobionic acid. Treated soils with increased soil water content are also described. The treated soils may include a soil enhancement agent absorbed into the soil. The soil enhancement agent may include at least one salt of a lactobionic acid. Cations from the at least one salt of a lactobionic acid may aggregate at least a portion of the particles in the soil.

Abstract: 6-oxo-1,4,5,6 tetrahydropyridazine-3-carboxylic acid or its salts or 1-methyl 6-oxo-1,4,5,6-tetrahydropyridizin-3-carboxylic acid or its salts, to plants can cause an increase in parameters such as germination, seedling emergence, growth, drought tolerance and recovery, yield, rhizobia induced root nodulation as compared to untreated wild type plants. 1-Methyl 6-oxo-1,4,5,6 tetrahydropyridazine-3-carboxylic acid or its salts is chemically the simplest 1-alkyl 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid and as such is an example showing the effectiveness of a 1-alkyl 6-oxo-1,4,5,6 tetrahydropyridazine-3-carboxylic acid. Higher series derivatives such as 1-alkyl 6-oxo-1,4,5,6 tetrahydropyridazine-3-carboxylic acids also induce beneficial effects on treated plants.

Abstract: A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals having an average particle size of 2-52 ?m.

Abstract: In certain embodiments, this disclosure relates to VIP and VIP agonists, optionally conjugated to nanoparticles, for use in methods of treating inflammatory T cell-mediated diseases or conditions, e.g., treating or preventing GvHD. In certain embodiments, this disclosure relates to methods of pulmonary administration of VIP and VIP agonists, optionally conjugated to nanoparticles. In certain embodiments, this disclosure contemplates nanoparticles disclosed herein.

Abstract: The invention aims to provide a crosslinked polymer having an excellent liquid absorption capacity and sufficient gel-pulverizability. The invention relates to a N-vinyl lactam-based crosslinked polymer including: a structural unit derived from a N-vinyl lactam-based monomer; and a structural unit derived from triallyl cyanurate, the N-vinyl lactam-based crosslinked polymer containing the structural unit derived from triallyl cyanurate in a ratio of 0.12 to 0.48 mol % to 100 mol % of all structural units.

Abstract: An oral colon-targeted delivery system is described, which includes a bacterial flora sensitive layer which contains polysaccharides and covers the exterior of active ingredients, a pH sensitive layer which contains any polymer composition dissolved under the condition of pH?7 and covers the exterior of the bacterial flora sensitive layer. A preparation method and applications of the delivery system are also described. According to the oral colon-targeted delivery system combined with the pH sensitive and bacterial flora sensitive mechanisms, the selective dissolution and release of active ingredients in the colon site are effectively improved by using double-layer protection so that the therapeutic or diagnostic effect is enhanced, and the application prospect is broad.

Abstract: The present invention is silver (I) periodate compounds and their use in preventing or reducing microbial contamination. The invention includes gels, coatings, and articles of manufacture having a surface contacted or coated with a gel comprising an antimicrobial silver (I) compound. Methods of treatment are also disclosed.

Abstract: A method for assessing susceptibility to nausea of a patient comprises assessing the GSH recycling dependent antioxidant activity of the patient's blood cells prior to receiving an emetogenic agent, e.g., a cytostatic agent or a surgical anesthetic.

Abstract: A powder formulation, or pharmaceutical composition comprising or consisting of particles of an antimuscarinic agent, said particles being obtainable by supercritical anti-solvent (SAS) precipitation and having a D50 of 4 ?m or less and a D90 of 10 ?m or less. Methods of forming the formulation and composition are also disclosed, as are uses of the composition.

Abstract: Compositions comprising a manganese mineral are provided. In specific embodiments, the manganese mineral contains manganese carbonate (MnCO3), which may be in the form of rhodochrosite. The compositions may be administered topically to a subject, or in some versions by inhalation. For example, the compositions may be administered by direct contact with the subject's skin or by inhalation through the subject's nasal passages or mouth. Such application of the disclosed compositions may increase the subject's collagen synthesis, prolidase activity (an enzyme responsible for collagen function), and manganese superoxide dismutase activity (an antioxidant having manganese in its active site) in the subject.

Abstract: This disclosure relates to picolinamides of Formula I and their use as fungicides.

Abstract: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Abstract: The invention relates to systems formed from closed liquid-tight packaging and a preferably dimensionally stable aqueous composition which is sealed therein and which, upon activation, releases a liquid phase essentially composed of water in a time-delayed manner. The invention further relates to methods for manufacturing such systems and the use thereof during the production of self-decomposing transdermal therapeutic systems (TTS).

Abstract: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Abstract: The present disclosure relates to methods and devices for controlling arthropods, including insects and arachnids in an environment. The methods generally comprise: generating a near-ideal gas Purified Hydrogen Peroxide Gas (PHPG) that is substantially non-hydrated (e.g., in the form of water in solution or water in solution or water molecules bonded by covalence, van der Waals forces, or London forces) and substantially free of, e.g., ozone, plasma species, and/or organic species; and directing the gas comprising primarily PHPG into the environment such that the PHPG acts to control arachnids in the environment. In certain aspects, the arachnids may be totally or partially killed.